177 related articles for article (PubMed ID: 24175302)
21. Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype.
Kolbe DL; DeLoia JA; Porter-Gill P; Strange M; Petrykowska HM; Guirguis A; Krivak TC; Brody LC; Elnitski L
PLoS One; 2012; 7(3):e32941. PubMed ID: 22403726
[TBL] [Abstract][Full Text] [Related]
22. Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethyation450 Beadchip assay to large population-based studies.
Wong EM; Joo JE; McLean CA; Baglietto L; English DR; Severi G; Hopper JL; Milne RL; FitzGerald LM; Giles GG; Southey MC
BMC Res Notes; 2015 Oct; 8():543. PubMed ID: 26438025
[TBL] [Abstract][Full Text] [Related]
23. The influence of DNA degradation in formalin-fixed, paraffin-embedded (FFPE) tissue on locus-specific methylation assessment by MS-HRM.
Daugaard I; Kjeldsen TE; Hager H; Hansen LL; Wojdacz TK
Exp Mol Pathol; 2015 Dec; 99(3):632-40. PubMed ID: 26551081
[TBL] [Abstract][Full Text] [Related]
24. Frequent aberrant methylation of the imprinted IGF2/H19 locus and LINE1 hypomethylation in ovarian carcinoma.
Dammann RH; Kirsch S; Schagdarsurengin U; Dansranjavin T; Gradhand E; Schmitt WD; Hauptmann S
Int J Oncol; 2010 Jan; 36(1):171-9. PubMed ID: 19956846
[TBL] [Abstract][Full Text] [Related]
25. Unique DNA methylation loci distinguish anatomic site and HPV status in head and neck squamous cell carcinoma.
Lleras RA; Smith RV; Adrien LR; Schlecht NF; Burk RD; Harris TM; Childs G; Prystowsky MB; Belbin TJ
Clin Cancer Res; 2013 Oct; 19(19):5444-55. PubMed ID: 23894057
[TBL] [Abstract][Full Text] [Related]
26. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas.
Vogt M; Munding J; Grüner M; Liffers ST; Verdoodt B; Hauk J; Steinstraesser L; Tannapfel A; Hermeking H
Virchows Arch; 2011 Mar; 458(3):313-22. PubMed ID: 21225432
[TBL] [Abstract][Full Text] [Related]
27. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.
Cicek MS; Koestler DC; Fridley BL; Kalli KR; Armasu SM; Larson MC; Wang C; Winham SJ; Vierkant RA; Rider DN; Block MS; Klotzle B; Konecny G; Winterhoff BJ; Hamidi H; Shridhar V; Fan JB; Visscher DW; Olson JE; Hartmann LC; Bibikova M; Chien J; Cunningham JM; Goode EL
Hum Mol Genet; 2013 Aug; 22(15):3038-47. PubMed ID: 23571109
[TBL] [Abstract][Full Text] [Related]
28. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
29. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.
Suzuki F; Akahira J; Miura I; Suzuki T; Ito K; Hayashi S; Sasano H; Yaegashi N
Cancer Sci; 2008 Dec; 99(12):2365-72. PubMed ID: 19032364
[TBL] [Abstract][Full Text] [Related]
30. Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.
Zhu X; Yang H; Lang J; Zhang Y
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():103-108. PubMed ID: 31242460
[TBL] [Abstract][Full Text] [Related]
31. Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer.
Sung HY; Yang SD; Park AK; Ju W; Ahn JH
Yonsei Med J; 2017 Jan; 58(1):27-34. PubMed ID: 27873492
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.
Huang RL; Gu F; Kirma NB; Ruan J; Chen CL; Wang HC; Liao YP; Chang CC; Yu MH; Pilrose JM; Thompson IM; Huang HC; Huang TH; Lai HC; Nephew KP
Epigenetics; 2013 Jun; 8(6):624-34. PubMed ID: 23774800
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneous DNA methylation status in same-cell subpopulations of ovarian cancer tissues.
Li Q; Xue X; Li W; Wang Q; Han L; Brunson T; Xu W; Chambers-Harris I; Wang Q; Li X; Ma L; Song Q
Tumour Biol; 2017 Jun; 39(6):1010428317701650. PubMed ID: 28618935
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation in the upstream CpG island of the GPER locus and its relationship with GPER expression in colon cancer cell lines.
Pal U; Ghosh S; Limaye AM
Mol Biol Rep; 2020 Oct; 47(10):7547-7555. PubMed ID: 32936384
[TBL] [Abstract][Full Text] [Related]
35. Bisulfite conversion-specific and methylation-specific PCR: a sensitive technique for accurate evaluation of CpG methylation.
Sasaki M; Anast J; Bassett W; Kawakami T; Sakuragi N; Dahiya R
Biochem Biophys Res Commun; 2003 Sep; 309(2):305-9. PubMed ID: 12951050
[TBL] [Abstract][Full Text] [Related]
36. [Ovarian cancer--modern approach to its origin and histogenesis].
Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2012 Jun; 83(6):454-7. PubMed ID: 22880466
[TBL] [Abstract][Full Text] [Related]
37. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization.
Ahluwalia A; Yan P; Hurteau JA; Bigsby RM; Jung SH; Huang TH; Nephew KP
Gynecol Oncol; 2001 Aug; 82(2):261-8. PubMed ID: 11531277
[TBL] [Abstract][Full Text] [Related]
38. Involvement of GATA-4/-5 transcription factors in ovarian carcinogenesis.
Wakana K; Akiyama Y; Aso T; Yuasa Y
Cancer Lett; 2006 Sep; 241(2):281-8. PubMed ID: 16337738
[TBL] [Abstract][Full Text] [Related]
39. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.
Milde-Langosch K; Ocon E; Becker G; Löning T
Int J Cancer; 1998 Feb; 79(1):61-5. PubMed ID: 9495360
[TBL] [Abstract][Full Text] [Related]
40. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
